A Phase 3 interventional study of Amiodarone in Ventricular Arrhythmias and Cardiac Arrest, sponsored by Versailles Hospital. Recruiting at 29 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by Versailles Hospital · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Heart Arrest with a site in France — 32 open to participants now, 33 under way, 3 of them phase 3. Heart Arrest · France.
Among the 106 studies in Heart Arrest with a site in France, this one is the 13th largest by planned enrollment of the 59 interventional ones that give a count, is one of 10 that started in 2025, is one of 13 in phase 3, reaches primary completion later than 12 of the 32 other live ones, and was the 93rd registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →32 of the 106 studies in Heart Arrest with a site in France are open now. Recruiting first, the newest first:
Nantes University Hospital · Sites in France, Belgium, Guadeloupe
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18+ · Healthy volunteers
Poitiers University Hospital · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 674 is above the median of 100 across 519 interventional studies indexed under Heart Arrest.
Median enrollment 106 across the 59 interventional studies, 150 across the 47 observational. Of the 62 that completed or were terminated, 3 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 106 have an industry lead sponsor. The 10 most frequent:
Versailles Hospital is the lead sponsor of 74 studies on the registry; 16 are open to participants now.
Versailles Hospital has 2 studies filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
8 of the studies in Heart Arrest with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06835491Phase 3Versailles HospitalProphylactic Anti-aRrhythmic Therapy With Amiodarone in Critically Ill Patients Admitted for an Out-of-hospital Cardiac Arrest With Initial Shockable Rhythm | 2027-01-15 |
| NCT03594318Versailles HospitalVersailles Hospital Cardiac Arrest Registry | 2026-12 |
| NCT06387225Nantes University HospitalEarly and Objective Assessment of Neurological Prognosis in Cardiac Arrest Patients | 2027-05-31 |
| NCT05961488CHU de ReimsPerformance of Coronary CT Angiography to Rule Out Coronary Artery Disease After Out-of-hospital Cardiac Arrest | 2027-06 |
| NCT06780722Nantes University HospitalStudy of the Occurrence of Cardiocirculatory Arrest as a Function of the Level of Hypoxemia During a Maastricht 3 Procedure | 2027-06-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 106 studies in Heart Arrest with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine if prophylactic administration of amiodarone for 72 hours in critically ill patients admitted after an OHCA with shockable rhythm, with a confirmed or a presumed cardiac cause, decreases the incidence of a composite endpoint of 30-day (starting from inclusion) all-cause mortality and/or severe in-hospital ventricular arrhythmia recurrence (ventricular fibrillation and/or ventricular tachycardia requiring intervention including re-arrest)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Initial loading dose of 300mg over 30 minutes in 250ml of glucose 5% solution. Continuous amiodarone infusion will be administered for 72 hours at a dose of 10 mg/kg without exceeding 900 mg/24h.
Drug: Amiodarone
Initial loading dose of 300mg over 30 minutes in 250ml of glucose 5% solution. Continuous amiodarone infusion will be administered for 72 hours at a dose of 10 mg/kg without exceeding 900 mg/24h.
Rate of Mortality and severe ventricular arrhythmia
The primary endpoint is a composite of 30-day (starting from inclusion) all-cause mortality and occurrence of severe in-hospital ventricular arrhythmia, defined by ventricular fibrillation and/or ventricular tachycardia requiring intervention occurring between inclusion and hospital discharge (or 30-day whichever the sooner).
Time frame: 30 days
outcomes related with cardiac events
* Occurrence of ventricular fibrillation (VF) * Occurrence of ventricular tachycardia (VT) requiring or not intervention * Occurrence of atrial fibrillation (AF) and supraventricular tachycardia * Occurrence of cardiac re-arrest due to asystole
Time frame: 90 days
outcomes related with mortality
* ICU mortality * Hospital (and 30-day) mortality * Day 90 mortality
Time frame: 90 days
Duration of invasive mechanical ventilation
Time frame: 90 days
Number of participants with outcomes related with amiodorane side effects
Number of the following side effects, patients could experimente (if applicable) during amiodarone infusion: * Conduction disorders * Hemodynamic consequences * Hepatic cytolysis * Anaphylaxis
Time frame: 5 days
Neurological outcome
M-Rankin scale (the lowest score is no handicap and the highest score is death) and Glasgow Outcome Score (the lowest score is the most severe coma)
Time frame: 90 days
Duration vasopressor infusion
Time frame: 90 days
Length of ICU stay
Time frame: 90 days
Length of stay in hospital
Time frame: 90 days
Dose of the anti-arrhythmic drugs
Time frame: 90 days
Number of days of anti-arrhythmic drugs
Time frame: 90 days
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Jan 2027, 14 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amiodarone
Versailles Hospital